Abstract: Background: Special operations forces (SOF) are at particular risk of suffering from Posttraumatic Stress Disorder (PTSD) due to an increased frequency of military deployment. At best, current FDA-approved interventions for PTSD, including pharmacological therapy, provide mild to moderate symptom relief. PTSD presents with broad-band electroencephalogram (EEG) abnormalities that may be amenable to neuromodulation that may be a novel therapeutic option for SOF veterans with PTSD. Methods: This was a retrospective chart review of a human performance program for SOF Veterans with PTSD symptoms who received individualized neuromodulation in the form of α-guided repetitive transcranial magnetic stimulation (α-rTMS) five days per week, with the magnetic pulse frequency set to their individual alpha frequency (IAF). Data on clinical scale scores at baseline and conclusion of treatment were extracted, including PTSD Checklist for DSM-5 (PCL-5) and side-effects. Results: Thirty-three (33) charts containing pre-post scales were reviewed. PTSD symptom severity decreased an average of 37.6% on the PCL-5 (p < .01). For participants with PCL-5 scores above the clinical threshold of 33, 69% no longer met clinical criteria for PTSD at the end of the human performance program. Side effects were consistent with those reported for standard TMS, most frequently headache and fatigue. Conclusions: Significant reductions in PTSD clinical severity were reported in SOF veterans who underwent α-rTMS. Side effects were equivalent to those observed in normal TMS. Data supports the need for α-rTMS clinical trials in the SOF veteran population to further demonstrate the clinical impact of this approach.